1.2 Antispasmodics and other drugs altering gut motility

Antimuscarinics

Hyoscine butylbromide

• Tablets 10mg (£12.00 = 20mg four times daily)
• Solution for injection 20mg in 1ml (£0.29 = 1ml ampoule)

Indications and dose

• Irritable bowel syndrome
  • By mouth: 10mg three times a day, increased if necessary up to 20mg four times a day
• Palliative care (specialist input)

Notes

1. MHRA Drug Safety Update (February 2017) Hyoscine butylbromide injection: risk of serious adverse effects in patients with underlying cardiac disease:
   1. hyoscine butylbromide injection can cause serious adverse effects including tachycardia, hypotension, and anaphylaxis
   2. these adverse effects can result in a fatal outcome in patients with underlying cardiac disease, such as those with heart failure, coronary heart disease, cardiac arrhythmia, or hypertension
   3. hyoscine butylbromide injection should be used with caution in patients with cardiac disease
   4. monitor these patients, and ensure that resuscitation equipment, and personnel who are trained how to use this equipment, are readily available
   5. hyoscine butylbromide injection remains contraindicated in patients with tachycardia

Sialanar®

(Glycopyrronium bromide)

• Oral solution SF 400micrograms/ml (320micrograms/ml glycopyrronium base) (£320.00 = 250ml)

Indications and dose

• Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
  • Child 3 -17 years: Dose is titrated according to the dosing tables given in the summary of product characteristics and is dependent on weight and therapeutic response.

Notes

1. Prescribe by brand: Different formulations of glycopyrronium oral solution are not bioequivalent
2. Unlicensed specials should not be prescribed.
3. Sialanar description on packaging and on GP prescribing systems is 320micrograms/ml – this is the amount of glycopyrronium BASE per ml and is equivalent to 400micrograms/ml of the SALT, glycopyrronium bromide
4. Specify doses as glycopyrronium bromide (not glycopyrronium base)
5. The routine commissioning of glycopyrronium bromide oral solution is accepted in Devon for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders (see Commissioning Policy for more details)
6. NICE NG62 recommends both glycopyrronium bromide oral solution and hyoscine hydrobromide transdermal patches (off-label, see section 4.6) as options to reduce the severity and frequency of drooling in children and young people with cerebral palsy. Glycopyrronium bromide is licensed for this indication but is available at significantly increased cost, and there is a lack of evidence of clinical benefit of glycopyrronium over hyoscine. Local specialists may indicate a preference for either drug as the first line treatment
7. The choice of treatment will be made by the specialist, taking into account the preferences of the child or young person and their parents or carers, and the age range and indication covered by the marketing authorisations.

Glycopyrronium bromide

• Injection 200 micrograms in 1ml ampoule (10 x 1ml = £9.96)
• Topical solution 0.05% (unlicensed preparation)

Indications

• Reduction of respiratory tract secretions (Just in case bags)
• Iontophoretic treatment of axillary hyperhidrosis (Hospital Only)

Notes

1. The circumstances under which treatments for focal hyperhidrosis are commissioned in Devon can be found in the commissioning policy

Antispasmodics

Mebeverine

• Tablets 135mg (£5.90 = 135mg three times daily)

Indications

• Irritable bowel syndrome

Dose

• 135mg three times daily

Peppermint oil

• Gastro-resistant capsules 0.2ml (£7.04 - £14.08)

Indications

• Irritable bowel syndrome

Dose

• 1–2 capsules, swallowed whole with water, 3 times daily

Notes

1. Avoid peppermint oil in patients with hiatus hernia or reflux. Peppermint oil may cause rectal stinging.
2. Mintec capsules should not be taken by patients with a history of allergy to aspirin or aspirin-like products

Last updated: 11-10-2019

 

Home > Formulary > Chapters > 1. Gastrointestinal > 1.2 Antispasmodics and other drugs altering gut motility

 

• First line
• Second line
• Specialist
• Hospital